Prostate Cancer

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.

Lancaster Urology, one of the largest urology practices in western Pennsylvania, fills the geographic void between Pittsburgh and Philadelphia by providing the whole spectrum of urologic care.

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for patients with intermediate- and high-risk prostate cancer.

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.

According to preliminary results from an ongoing trial, half of a small group of patients with metastatic castration-resistant prostate cancer had a PSA response during treatment with the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib (Lynparza).

According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

Padeliporfin vascular-targeted photodynamic therapy, a novel tissue-preserving treatment, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy, according to the results of a phase III trial.

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses MRI fusion-guided biopsy in patients with prostate cancer.

Up to 94% of patients with metastatic castration-resistant prostate cancer have circulating tumor DNA with at least 1 genetic alteration, suggesting ctDNA could be a noninvasive alternative to traditional tumor biopsies and help personalize treatment in this setting.

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses patients with prostate cancer who are best suited to be treated with robotic surgery.

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential that liquid biopsies will have in the treatment landscape of prostate cancer.

Richard Harris, MD, urologist, UroPartners, discusses the respective roles of PSA testing and active surveillance in the treatment of patients with prostate cancer.

The addition of hormonal therapy to radiation treatment following surgery significantly improved survival in patients with recurrent prostate cancer, according to the results of a study published in The New England Journal of Medicine.

Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.

Philip W. Kantoff, MD, chair of the Department of Medicine, Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the combination of docetaxel (Taxotere) chemotherapy and androgen deprivation therapy (ADT) in the setting of metastatic hormone-sensitive prostate cancer.

Dana E. Rathkopf, MD, Memorial Sloan Kettering Cancer Center, discusses the emergence of the androgen receptor splice variant-7 (AR-V7) biomarker in the treatment of patients with prostate cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.

David Albala, MD, discusses the uses and benefits of robotic urological surgery in prostate cancer, as well as methods to achieve better physician compliance.

Richard Harris, MD, urologist, UroPartners, discusses PSA testing for patients with prostate cancer and the controversial grade D recommendation of the United States Task Force.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the challenges that remain with the use of docetaxel to treat patients with prostate cancer.

Carl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.

A sharp decline has been observed in the overall rate of men receiving treatment for prostate cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Robert Dreicer, MD, associate director for clinical research and deputy director of the University of Virginia Cancer Center, discusses the questions that surround radium-223.

Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.